Ubs Group Ag Minerva Neurosciences, Inc. Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
A detailed history of Ubs Group Ag transactions in Minerva Neurosciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,621 shares of NERV stock, worth $2,285. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,621
Previous 12
13408.33%
Holding current value
$2,285
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding NERV
# of Institutions
19Shares Held
1.95MCall Options Held
0Put Options Held
0-
Federated Hermes, Inc. Pittsburgh, PA1.35MShares$1.91 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA252KShares$355,4040.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny114KShares$160,8760.0% of portfolio
-
Geode Capital Management, LLC Boston, MA76.7KShares$108,1920.0% of portfolio
-
Black Rock Inc. New York, NY72.7KShares$102,4630.0% of portfolio
About Minerva Neurosciences, Inc.
- Ticker NERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,340,190
- Market Cap $7.53M
- Description
- Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein ...